ORGO Q3 2021 Earnings — Organogenesis Holdings Inc. Revenue & Financial Results | Market Cap Arena

ORGOOrganogenesis Holdings Inc.

$338M

Q3 2021 Earnings

Healthcare Drug Manufacturers - Specialty & Generic

Income Statement

Revenue

$114M+12.9% YoY

Gross Profit

$88M77.0% margin

Operating Income

$16M14.3% margin

Net Income

$13M11.1% margin

EPS (Diluted)

$0.09

QoQ Revenue Growth

-7.7%

Cash Flow

Operating Cash Flow

$28M

Free Cash Flow

$11M

Stock-Based Comp.

$1M

Balance Sheet

Total Assets

$370M

Total Liabilities

$181M

Stockholders' Equity

$189M

Cash & Equivalents

$102M

Year-over-Year Comparison

Metric	Current	Year Ago	Change
Revenue	$114M	$101M	+12.9%
Gross Profit	$88M	$78M	+12.5%
Operating Income	$16M	$23M	-28.7%
Net Income	$13M	$21M	-39.4%

Revenue Segments

Advanced Wound care

$107M94%

Surgical and Sports Medicine

$6M6%